Skip to Main Content

5,885

Views

24

CrossRef citations to date

0

Altmetric

Clinical Trials

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

Jeremy M. ShefnerDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA, ;Department of Neurology, University of Arizona, Phoenix, AZ, USA, Correspondence[email protected]
View further author information

,

Merit E. CudkowiczDepartment of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA, View further author information

,

Orla HardimanAcademic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland, View further author information

,

Bettina M. CockroftCytokinetics, Inc, South San Francisco, CA, USA, and View further author information

,

Jacqueline H. LeeCytokinetics, Inc, South San Francisco, CA, USA, and View further author information

,

Fady I. MalikCytokinetics, Inc, South San Francisco, CA, USA, and View further author information

,

Lisa MengCytokinetics, Inc, South San Francisco, CA, USA, and View further author information

,

Stacy A. RudnickiCytokinetics, Inc, South San Francisco, CA, USA, and View further author information

,

Andrew A. WolffCytokinetics, Inc, South San Francisco, CA, USA, and View further author information

,

Jinsy A. AndrewsThe Neurological Institute, Columbia University, New York, NY, USAView further author information

& on behalf of the VITALITY-ALS STUDY GROUP show all